StockData
AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Aardvark Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.74−0.04 (-1.06%)

Close on Oct 19, 2026

Market cap
$81.70M
P/E (TTM)
–
Dividend yield
–

Community

Notes and questions about Aardvark Therapeutics from other investors

No posts about AARD yet

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.